EUVIMEDOpdag EUVIMED
VergleichsstudieOpen access

Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery

Avery Brown, Suhani S Patel, Akio Kozato iD, Babak J Orandi, Allan Massie, Alexander Hien Vu, Eduardo Somoza, Tony Mei, Sunita Desai, Donglan S Zhang, Dorry Segev, Akuezunkpa Ude Welcome and 3 more

Obesity · 2026-08 · 34 (8) · 1583-1591

DOI: 10.1002/oby.70246 ↗

At a glance

Vergleichsstudie in Obesity, published online on 2026-06-25. Written by Avery Brown and 14 co-authors. Institution: Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA. Major MEDLINE topics: Tirzepatide, Glucagon-Like Peptides, Bariatric Surgery, Obesity, Morbid. Cited 4 times so far (Crossref); 29 references. The full text is freely available in PubMed Central. Funded by: NCATS NIH HHS, NIDDK NIH HHS, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Directly compare the real‐world effectiveness of semaglutide and tirzepatide to bariatric operations: sleeve gastrectomy and gastric bypass.

Methods

This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP‐1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024. Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models. Intention‐to‐treat (any GLP‐1RA) and per‐protocol (1 year of continuous GLP‐1RA orders) analyses were performed.

Results

Of 44,025 patients studied, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years post treatment: semaglutide ( n = 25,804) TWL (95% CI): 5.4% (5.3%–5.6%), 6.5% (6.4%–6.7%), and 7.4% (7.3%–7.6%); tirzepatide ( n = 7308): 9.1% (8.9%–9.4%) and 10.8% (10.2%–11.3%); sleeve gastrectomy ( n = 8728): 24.4% (24.3%–24.6%), 22.4% (22.3%–22.5%), and 22.0% (21.8%–22.1%); gastric bypass ( n = 2185): 29.8% (29.7%–29.9%), 28.1% (28.0%–28.2%), and 28.4% (28.3%–28.5%). With 1 year of continuous GLP‐1RA, findings were: semaglutide TWL: 7.2% (7.0%–7.4%), 8.0% (7.8%–8.2%), and 8.8% (8.6%–9.0%); tirzepatide TWL: 11.7% (11.4%–11.9%) and 11.9% (11.5%–12.3%).

Conclusions

In this retrospective two‐center study, bariatric surgery was associated with greater weight loss than GLP‐1RAs among patients eligible for both options.

Subjects

MeSH terms (MEDLINE)

TirzepatideGlucagon-Like PeptidesBariatric SurgeryObesity, MorbidHumansSemaglutideFemaleWeight LossMiddle AgedAdultMaleTreatment OutcomeGastric Bypass

Substances

SemaglutideTirzepatideGlucagon-Like Peptides

Authors and institutions

  • Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA.
  • Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
  • Center for Surgical and Transplant Applied Research, NYU Langone Health, New York, New York, USA.
  • Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Surgery, NYU Langone Hospital-Brooklyn, Brooklyn, New York, USA.

ORCID profiles: Akio Kozato, Karan R Chhabra

Funding

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Brown, A., Patel, S. S., Kozato, A., Orandi, B. J., Massie, A., Vu, A. H., Somoza, E., Mei, T., Desai, S., Zhang, D. S., Segev, D., Welcome, A. U., Ren-Fielding, C., Parikh, M., & Chhabra, K. R. (2026). Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity, 34(8), 1583-1591. https://doi.org/10.1002/oby.70246

Vancouver

Brown A, Patel SS, Kozato A, Orandi BJ, Massie A, Vu AH, et al. Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity. 2026;34(8):1583-1591. doi:10.1002/oby.70246

BibTeX
@article{Brown2026,
  author = {Brown, Avery and Patel, Suhani S and Kozato, Akio and Orandi, Babak J and Massie, Allan and Vu, Alexander Hien and Somoza, Eduardo and Mei, Tony and Desai, Sunita and Zhang, Donglan S and Segev, Dorry and Welcome, Akuezunkpa Ude and Ren-Fielding, Christine and Parikh, Manish and Chhabra, Karan R},
  title = {Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {8},
  pages = {1583--1591},
  doi = {10.1002/oby.70246}
}
Start for free →